C07K 2317/64
Comprising a combination of variable region and constant region components
Official title: comprising a combination of variable region and constant region components
C07K2317/64 (Comprising a combination of variable region and constant region components) appears on 879 US grants and 1,935 published applications in this corpus.
Search patents in C07K- Granted patents
- 879
- Published applications
- 1,935
- Assignees
- 620
- Inventors
- 3,457
- Latest grant
- 15 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1998 | 3 | 0 |
| 1999 | 3 | 0 |
| 2000 | 1 | 0 |
| 2001 | 0 | 0 |
| 2002 | 0 | 1 |
| 2003 | 1 | 6 |
| 2004 | 0 | 5 |
| 2005 | 0 | 13 |
| 2006 | 1 | 10 |
| 2007 | 4 | 4 |
| 2008 | 2 | 5 |
| 2009 | 4 | 16 |
| 2010 | 4 | 28 |
| 2011 | 4 | 29 |
| 2012 | 6 | 32 |
| 2013 | 14 | 78 |
| 2014 | 28 | 99 |
| 2015 | 54 | 91 |
| 2016 | 51 | 94 |
| 2017 | 68 | 115 |
| 2018 | 56 | 107 |
| 2019 | 61 | 95 |
| 2020 | 82 | 120 |
| 2021 | 62 | 156 |
| 2022 | 74 | 152 |
| 2023 | 63 | 192 |
| 2024 | 87 | 195 |
| 2025 | 96 | 162 |
| 2026 | 50 | 130 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Multi-specific antibodies and methods of making and using thereof15 Sep 2026US 12,735,487 B2Systimmune, Inc.
- Bispecific anti-human a-beta/human transferrin receptor antibodies and methods of use15 Sep 2026US 12,735,497 B2Hoffmann-La Roche Inc.
- Protease-processed molecules1 Sep 2026US 12,723,106 B2Sanofi
- Single chain VH and heavy chain antibodies25 Aug 2026US 12,715,906 B2Trianni, Inc.
- Antibodies binding to GPRC5D25 Aug 2026US 12,715,923 B2Hoffmann-La Roche Inc.
- Cd137 binding molecules and uses thereof1 Oct 2026US 2026/0297209 A1MacroGenics, Inc.
- Monospecific anti-frizzled antibodies and methods of use24 Sep 2026US 2026/0285987 A1Surrozen Operating, Inc.
- Developing an anti-human cd45 imaging probe for noninvasive detection of human immune cells10 Sep 2026US 2026/0263647 A1Dana-Farber Cancer Institute, Inc.
- Bispecific t cell activating antigen binding molecules10 Sep 2026US 2026/0265377 A1Hoffmann-La Roche Inc.
- Sars-cov-2 antibodies and bispecific antibodies27 Aug 2026US 2026/0250363 A1AP Biosciences, Inc.
Most cited
By later US patents
- Humanised antibodies1,093US 5,859,205 ACelltech Limited · 1999
- Humanized antibodies528US 6,632,927 B2Celltech Therapeutics Limited · 2003
- Dual variable domain immunoglobulin and uses thereof391US 7,612,181 B2Abbott Laboratories · 2009
- CD3 specific recombinant antibody192US 5,929,212 ACelltech Therapeutics Limited · 1999
- Dual variable domain immunoglobulin and uses thereof187US 8,258,268 B2Abbott Laboratories · 2012